NL-OMON37195已完成2 期
A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa - BEZ235 in PEComa
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologically confirmed diagnosis of malgnant PEComa (included epithelioid angiomyolipoma (AML) in adult patients
- •Unresectable/advanced and/ or metastatic and documented progressive measurable disease
- •Treated with 1 or 2 prior lines of treatment
排除标准
- •Disease exclusions: Lymphangioleiomyomatosis (LAM) exclusively
- •Active uncontrolled or symptomatic CNS metastases, concurent malignancy or malignancy in last three years.
- •Concurrent severe and/or uncontrolled medical condition (for details see protocol)
研究者
相似试验
进行中（未招募）
不适用
Safety and efficacy of BEZ235 in patients with perivascular epithelioid cell tumors (PEComas)Adult patient with metastatic or unresectable malignant perivascular epithelioid cell tumors (PEComa)MedDRA version: 14.1Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001884-39-ESovartis Farmaceutica S.A.33
进行中（未招募）
不适用
Safety and efficacy of BEZ235 in patients with perivascular epithelioid cell tumors (PEComas)EUCTR2011-001884-39-NLovartis Pharma Services AG33
进行中（未招募）
不适用
Safety and efficacy of BEZ235 in patients with perivascular epithelioid cell tumors (PEComas)EUCTR2011-001884-39-HUovartis Pharma Services AG33
进行中（未招募）
不适用
Safety and efficacy of BEZ235 in patients with perivascular epithelioid cell tumors (PEComas)Adult patient with metastatic or unresectable malignant perivascular epithelioid cell tumors (PEComa)MedDRA version: 14.1Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001884-39-ITOVARTIS FARMA33
进行中（未招募）
不适用
A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathwaypatients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathwayMedDRA version: 13.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024394-39-GBovartis Pharma Services AG120